SPONSOR

Pfizer

Total Trials

Recruiting

Phases

Phase 1, Phase 3, Phase 2, Phase 1, Phase 2, Phase 4

Conditions studied: Healthy Participant Healthy Carcinoma Non-Small-Cell Lung Lung Cancer (NSCLC)Lung Neoplasms Carcinoma, Non-Small-Cell Lung (NSCLC)Lung Disease Non-Small Cell Lung Cancer Non-small Cell Lung Cancer, Non-squamous

Pfizer is one of the largest biopharmaceutical companies in the world by research expenditure, with a clinical trial portfolio spanning oncology, rare diseases, vaccines, immunology, internal medicine, and neurology. Founded in 1849, Pfizer has brought more than 350 medicines and vaccines to patients globally, and today maintains one of the broadest Phase 2 and Phase 3 pipelines in the industry. Their clinical research operations span over 150 countries, making Pfizer trials accessible to a wide and diverse patient population.

Pfizer's oncology program — operating largely through its Pfizer Oncology unit — focuses on precision treatments including CDK4/6 inhibitors (palbociclib), EGFR-targeted therapies, antibody-drug conjugates, and immuno-oncology agents. Outside of cancer, Pfizer conducts extensive trials in cardiovascular and metabolic disease (including its ATTR cardiomyopathy drug tafamidis), rare pediatric conditions, and infectious disease. The COVID-19 mRNA vaccine program, conducted in partnership with BioNTech, included one of the largest Phase 3 vaccine trials in history with over 40,000 participants across six countries.

Participants in Pfizer-sponsored trials receive investigational treatments at no cost and are monitored by independent Data Safety Monitoring Boards. Pfizer trial sites are typically major academic medical centers, teaching hospitals, and specialist clinical research organizations. Eligibility criteria vary by study; most trials are listed on ClinicalTrials.gov with a direct contact link to the enrolling site.

Frequently Asked Questions — Pfizer

What therapeutic areas does Pfizer focus on in its clinical trials?

Pfizer's active clinical trial portfolio is concentrated across six primary therapeutic areas: oncology (including breast, lung, prostate, and hematologic cancers), rare diseases and gene therapy, vaccines and antivirals, internal medicine (heart failure, cardiomyopathy, metabolic disease), immunology and inflammation (rheumatoid arthritis, lupus, IBD), and neuroscience. Within oncology specifically, Pfizer runs a large number of Phase 1 and Phase 2 basket trials testing targeted agents across multiple tumor types simultaneously.

How are Pfizer clinical trial sites selected, and where are they located?

Pfizer selects trial sites based on investigator expertise, patient access, infrastructure capacity, and local regulatory readiness. The majority of Pfizer-sponsored trials operate across North America, Western Europe, and increasingly Asia-Pacific and Latin America to ensure diverse participant populations. In the United States, Pfizer frequently partners with NCI-designated cancer centers, major academic medical centers such as MD Anderson, Memorial Sloan Kettering, and Mayo Clinic, as well as community oncology networks. Site-level contact information for each trial is available on ClinicalTrials.gov.

Does participating in a Pfizer trial mean receiving an experimental drug?

Not necessarily. Many Pfizer trials include randomized controlled designs in which some participants receive the investigational treatment while others receive an active comparator (an approved standard-of-care therapy) or, in some cases, a placebo — always disclosed in the informed consent process. Participants never pay for investigational drugs, and in many trials receive study-related medical assessments at no cost. Pfizer trials are conducted under FDA and EMA oversight and follow ICH Good Clinical Practice guidelines.

Pfizer

Frequently Asked Questions — Pfizer

Clinical Trials by Pfizer

A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy Adults

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults